Prolactinoma is the most common pituitary tumour in adults. Macroprolactinomas, particularly in men, may occasionally exhibit a very aggressive clinical course as evidenced by progressive growth, invasion through bone into the sphenoid sinus, cavernous sinus, suprasellar region or the nasopharynx. Some may even progress to pituitary carcinoma with craniospinal or systemic metastases. Aggressive tumours have low cure rates despite appropriate medical and surgical treatment. The mechanisms underlying this aggressive biological behaviour have not yet been fully clarified. Recent immunohistochemical, molecular and genetic studies have provided some insight in this respect. Invasive prolactinomas may be associated with a high Ki-67/MIB-1 labelling index indicating increased cell proliferation, although this is not a universal finding. The AA polymorphism in the cyclin adenine (A)/guanine (G) gene is more frequently detected in invasive prolactinomas. Increased expression of the polysialylated neural cell adhesion molecule (NCAM) and reduced expression of the E-cadherin/catenin complex implies a contribution of altered cell-to-cell adhesion and cellular migration. Extracellular matrix components (ECM), matrix metalloproteinases (MMPs) and their inhibitors play important roles in the context of angiogenesis and invasion. The induction of fibroblast growth factor and vascular endothelial growth factor via oestrogen-induced overexpression of novel genes (PTTG, hst and Edpm5) enhance cell growth, proliferation and angiogenesis contributing to invasiveness in prolactinomas. Although mutations in proto-oncogenes like Ras are uncommon, loss of tumour suppressor genes at loci 11q13, 13q12-14, 10q and 1p seem to be associated with invasiveness. Of the described mechanisms, only reduced E-cadherin/catenin expression and overexpression of hst gene seem to be relatively specific markers for prolactinoma invasiveness compared with other pituitary adenomas. Further research is needed to clarify the molecular mechanisms behind the aggressive course of some prolactinomas to predict those with a potentially poor clinical outcome, and to devise treatments that will eventually enable the cure of these challenging tumours.
Introduction
Prolactinoma is the most common pituitary tumour in adults accounting for 60% of all functioning pituitary adenomas (1) . Prolactinomas show various initial presentations, radiological appearances and biological behaviour. In general, prolactinomas in women of childbearing age are indolent microadenomas (!10 mm in diameter) (2) (3) (4) (5) . These patients come to medical attention due to the effects of hyperprolactinaemia, for example, galactorrhea, oligomenorrhea, loss of libido and sexual dysfunction (6) . In contrast, men and post-menopausal women frequently harbour a macroprolactinoma (O10 mm in diameter) with or without extrasellar extension (7, 8) . Apart from signs of hyperprolactinaemia, patients with macroadenomas with extrasellar extension generally seek medical attention due to mass effect. These patients may present with headache, visual disturbances, cranial nerve palsies, hypopituitarism (9) or rarely spontaneous cerebrospinal fluid leakage (10) , epilepsy due to temporal lobe compression and obstructive hydrocephalus (11) .
The mechanisms of aggressive biological behaviour of some prolactinomas, despite their mostly benign histopathological features, have not yet been fully defined. There is inconsistency in the definition of 'aggressiveness' in prolactinomas. From the clinical point of view, the most important factors to take into account are resistance to dopamine agonists and high recurrence rates after surgery. From the radiological point of view, the tumours are considered as aggressive if they show invasion into adjacent structures such as the cavernous sinus. The lack of any increase in tumour size in the majority of patients with microadenoma is compatible with the frequent incidental finding of these tumours in unselected autopsy cases (12, 13) . The risk of progression from a microadenoma to a macroadenoma is estimated to be about 4-7% (1) . This observation suggests that aggressive macroadenoma may represent a different and distinct entity (14, 15) . There are no clear-cut criteria to predict biological behaviour in prolactinomas (16, 17) . As mentioned previously, some prolactinomas are able to invade the surrounding structures and tissues. These are called 'invasive prolactinomas'. Presently, local invasion per se is not considered a sign of malignancy. Only rare pituitary tumours with distant metastases are termed 'pituitary carcinomas', indicating truly malignant behaviour. Their pattern of spread may be craniospinal, systemic or both. Traditional histopathological features of malignancy (nuclear polymorphism, high cellularity, cytological atypia, the presence of necrosis and nucleolar prominence) are not generally helpful to discriminate the pituitary carcinomas from benign adenomas (18) . When mitotic figures are present, they do provide some insight into the potentially aggressive nature of the tumour, but their discriminating power is somewhat limited (17) .
The World Health Organization (WHO) classification of endocrine tumours has defined an 'atypical pituitary adenoma' as one having an elevated mitotic activity, a Ki-67 labelling index O3%, and p53 (a nuclear phosphoprotein whose immunohistochemical accumulation has served as an unfavourable prognostic factor for a wide range of human neoplasms) immunoreactivity O3% (19, 20) . These features are generally lacking in non-invasive adenomas. Nearly, all pituitary carcinomas present the above-mentioned histological features of atypical adenomas (21) .
There is also a problem in assessing the invasiveness of a particular tumour, since there are various methods used to define it. For example, the spectrum of invasiveness may encompass radiological invasion, intraoperative observations by the surgeon or microscopical invasion. It has also been proposed that a tumour, which extends into the adjacent structures according to imaging, may not represent an invasive one on microscopy (16) . With the advancement of techniques in genetics, molecular biology and immunohistochemistry in the past two decades, more specific markers have been identified which might more precisely indicate an aggressive potential in these tumours.
In this review, after briefly reviewing the biochemical, neuroradiological and clinical aspects of aggressiveness (i.e. tumoural expansion and invasion through the surrounding and even remote structures causing difficulties in management and low cure rates), we will address suggested markers which may help identify these tumours in the context of cell proliferation, cell cycling, cell-to-cell adhesion, angiogenesis, alterations of extracellular matrix (ECM) components and growth factor signalling. We will also summarise the genetic alterations leading to changes in proliferative capacity and angiogenesis in prolactinomas. The contribution of some of these markers to gender differences in prolactinoma behaviour and the development of resistance to dopaminergic agonists will also be discussed. We should acknowledge, however, that the studies that will be reviewed in this paper are based on surgically removed prolactinomas. As surgical therapy for these tumours is performed in particular subsets of patients only, an inevitable selection bias may be envisioned in all these studies.
Biochemical and radiological assessment of aggressive prolactinomas
Hormone-secreting pituitary adenomas are readily diagnosed by endocrine testing which can be routinely performed. In giant prolactinomas, the diagnosis is generally straightforward, since they present with extreme elevation of prolactin (even O100 000 ng/ml). Prolactinomas are unique in the sense that dopamine agonists usually cause rapid tumour shrinkage with relief in compressive symptoms (22) (23) (24) . So, it is important to diagnose a prolactinoma patient before considering surgery as a first step treatment modality. Clinicians should also be aware of the 'high dose hook effect' while interpreting a low prolactin level in a patient with giant invasive pituitary adenoma (25, 26) .
Calle-Rodrigue et al. (27) have shown that preoperative serum prolactin concentrations were significantly higher in invasive prolactinomas compared with the non-invasive ones (median prolactin levels 705 vs 141 ng/ml respectively). When prolactin cut-off was chosen as 3300 ng/ml, the specificity for predicting an invasive prolactinoma was 91% (sensitivity was not calculated). Similarly, Ma et al. (28) have reported that prolactinomas invading the cavernous sinus had significantly higher prolactin concentrations and tumour sizes, and furthermore, that preoperative prolactin levels were significantly associated with invasiveness. No comparisons have been done in these studies (27, 28) , however, regarding plurihormonal adenomas co-secreting prolactin versus pure prolactinsecreting adenomas in terms of aggressive behaviour as evidenced by invasiveness. These data suggest that prolactin levels correlate with tumour size and that high preoperative prolactin levels indicate the presence of an invasive prolactinoma.
Although magnetic resonance imaging (MRI) is the best technique for assessing the extent of the tumour, computerised tomography (CT) provides better information about interruption of the sellar floor and intratumoural calcification. From the radiological point of view, aggressiveness in these tumours is probably best reflected by cavernous sinus invasion.
Recently, Cottier et al. (29) defined MRI-based criteria for the diagnosis of cavernous sinus invasion using the surgical findings of 106 patients as standard-of-reference criteria for invasion. Invasion of the cavernous sinus was certain (positive predictive value (PPV) 100%) if the percentage of the encasement of the internal carotid artery (ICA) by tumour was 67% or greater. Invasion was considered to be highly probable if the carotid sulcus venous compartment was not depicted (PPV 95%) or the line joining the lateral wall of the intracavernous and supracavernous ICAs was passed by the tumour (PPV 85%). If the percentage of the encasement of the intracavernous ICA is lower than 25, or the line joining the medial wall of the intracavernous and supracavernous ICAs was not passed by the tumour, cavernous sinus invasion by the tumour is excluded.
Resistance to dopaminergic agonists: not a 'sine qua non' of aggressiveness
There is no consistency in the literature about what constitutes resistance to dopamine agonists. Failure to normalise prolactin levels independently of the baseline value, or failure to reduce prolactin levels below 50% of baseline have been considered as resistance. Similar arguments are valid for tumour size reduction as well. There may be discordance in the response of a given patient with respect to prolactin reduction and tumour size reduction (for review, see 30). While dopamine agonists or surgery cure most non-invasive prolactinomas, invasive ones may not be cured by surgery alone requiring additional treatments like radiotherapy (31) . Furthermore, they may have a propensity to be resistant to dopamine agonists. However, dopaminergic agonists should still be considered as the first-line treatment in most patients with giant prolactinomas. Wu et al. (26) have recently demonstrated that bromocriptine treatment of invasive giant prolactinomas after a mean follow-up of 37 months results in improvement of clinical symptoms in almost all patients, as well as tumour volume reduction by a mean of 93.3%. Failure to normalise prolactin levels is found in about 25% of patients treated with bromocriptine and in 10-15% of those treated with pergolide or cabergoline in prolactinomas regardless of size or invasiveness (30) . Resistance of the tumour to shrinkage with bromocriptine is seen in about 50% of the tumours, while this figure is about 10-15% with cabergoline and pergolide (30) . Another important drug, which has been used in bromocriptineresistant tumours and in patients with intolerance to bromocriptine, is the non-ergot dopamine agonist quinagolide. It is very difficult to verify the incidence of primary quinagolide resistance in prolactinomas. In a recent crossover longitudinal study, Di Sarno et al. (32) have shown that quinagolide treatment normalised prolactin levels in all microprolactinomas, and 87.5% of macroprolactinomas. These figures were almost the same for treatment with cabergoline (32) .
Drug resistance is more common in macroadenomas compared with microadenomas. For example, in a retrospective analysis, a group of patients who were initially being treated with bromocriptine was switched to cabergoline (33) . Bromocriptine resistance in terms of prolactin normalisation was more frequent in macroprolactinomas (54%) than microprolactinomas (43%). Resistance to cabergoline was 18 and 10% in macroand microadenomas respectively. The underlying mechanism leading to the resistance in most tumours has been attributed to decreased cellular D2 receptors with lower affinities to their ligands (34) .
Macroprolactinomas in men tend to be more frequently resistant to bromocriptine therapy than those in women (8). Delgrange et al. (8) have shown significant differences in frequencies of bromocriptine resistance between males (30%) and females (5%). The correlation of drug resistance with other markers of aggressiveness, in particular the ones related with proliferative capacity, will be discussed in the following part to provide an explanation to this gender difference in biological behaviour of these tumours.
Specific markers implicated in aggressiveness in prolactinomas

Implications of proliferative capacity, cell cycling and cell-to-cell adhesion in prolactinoma behaviour
It is well known that tumour expansion and invasion primarily relate to several mechanisms, including increases in cell proliferation, changes in cell cycling and cell-to-cell adhesion. Several markers have been investigated in prolactinomas in an attempt to relate these mechanisms with aggressive tumour biology. Some of the studies that may be relevant are given in Table 1 , and are further discussed in the following paragraphs taking into account the inconsistent and controversial issues in the literature.
Markers of proliferation
Nuclear proteins, such as Ki-67 and proliferating cell nuclear antigen (PCNA) are often used to assess proliferative activity of tumour cells (16) . Ki-67 is recognised by the MIB-1 monoclonal antibody and it is expressed throughout the cell cycle in G1, S, G2 and M phases, but not the quiescent G0 phase (28, 35) . The percentage of cells immunostained for this protein (Ki-67/MIB-1 labelling index) represents a reliable marker of proliferative activity (36) . PCNA is a protein that accumulates in the nucleus during the cell cycle. It has a higher specificity for the S phase than Ki-67, and labels only those cells that passed the important G1/S boundary (37) . A comparison of Ki-67 and PCNA proliferation in pituitary tumours has shown that PCNA overestimates the cell proliferation in these tumours when tumours with a labelling index !0.1% were considered to be negative for proliferation (38) . Concerning prolactinomas, DelGrange et al. (8) found no significant difference in PCNA index between invasive and non-invasive prolactinomas. Similar to the PCNA index, numerous studies have been performed on the Ki-67/MIB-1 labelling index in pituitary adenomas with inconsistent results in terms of correlation with clinical presentation. With respect to non-functioning adenomas, no significant relationship has been found between the clinical course and the labelling index (39) . The predictive ability of the Ki-67/MIB-1 labelling index for aggressive behaviour is greater in functioning pituitary adenomas, including prolactinomas. In a series reported by Thapar et al. (36) , hormone-secreting adenomas had a significantly higher mean labelling index (3.25%) than non-functioning adenomas (2.06%). The highest labelling indices were in prolactinomas. A cut-off of 3% of labelling as an indicator of invasiveness had a specificity of 97.3% and a sensitivity of 73% (36) .
Two studies have shown higher levels of the labelling indices in males with macroprolactinomas when compared with similar tumours in female patients (8, 28) . Regarding the association of Ki-67/MIB-1 labelling index with tumour behaviour, these studies (8, 28) did not find consistent differences between invasive and non-invasive macroprolactinomas except in a small group of males (nZ4) with dopamine agonist-resistant invasive prolactinomas. The mean labelling index was 4.7% compared with !1% in all tumours that are responsive (8) . PCNA labelling yielded similar results (8) . On the other hand, one recent study by Ma et al. (28) , conducted in 123 Japanese prolactinoma patients, found no association between Ki-67 labelling index and clinical parameters. In this study, half of the cases were pure prolactin-producing tumours while the other half was plurihormonal prolactinomas. No significant association could be detected between proliferative capacities and tumour size. The impact of patient age and gender in both plurihormonal tumours and pure prolactinomas was not assessed (28) . Recently, Scheithauer et al. (21) found no statistically significant difference between invasive and non-invasive adenomas (including prolactinomas) with respect to Ki-67 and PCNA labelling indices. The level of p53 expression was also similar between the groups. Ki-67 labelling and p53 were not statistically significant in determining adenomas prone to recur. It should be emphasised that the difference between the Ki-67 results of Scheithauer et al. Proteins implicated in cell cycling Cyclins and cyclindependent kinases (CDK) are essential for cell cycle regulation in eukaryotes. Active cyclin-CDK complexes drive cells through cell cycle phases by phosphorylating the protein substrates that are essential to achieve transition to the next phase. The levels of cyclins are regulated at the level of transcription and also by targeted degradation via the ubiquitin pathway (40). Jordan et al. (41) have found that non-functioning adenomas and functioning invasive tumours, including prolactinomas significantly express cyclin D1 to a greater extent than non-invasive tumours and the normal pituitary gland. Pituitary carcinomas did not appear to be different from the benign tumours in terms of cyclin expression (41) . We have previously observed that it was only cyclin E expression that was higher in macroprolactinomas than microprolactinomas (42) . Since cyclin E is expressed maximally at G1/S transition of the cell cycle and thought to be important in the initiation of DNA replication, it may have an implication in growth and expansion of prolactinomas (43) . This warrants further analysis in Table 1 Detected markers of aggressiveness related to cell proliferation, cell cycling and cell-to-cell adhesion.
Category
Marker Status of expression and clinical relevance Ref. larger prolactinoma groups categorised according to their invasiveness or recurrence rate. The cyclin D1 gene contains a frequent A/G polymorphism within the splice donor region of exon 4/intron 4 (44) . The cyclin D1 genotype is associated with clinical outcome, particularly the survival after diagnosis, in a significant number of neoplasms (44, 45) . In a cohort of 294 (20% were prolactinomas) pituitary adenomas, Simpson et al. (46) examined the distribution of cyclin D1 A/G polymorphisms across the Hardy grade of the tumours. Grade 3 and 4 tumours were considered as invasive. When the data were analysed separately in the prolactinoma subgroup, the authors observed a progressive increase in AA genotype from grade 1 (11%) through grade 4 (66%), while the GG genotype progressively decreased from grade 1 (43%) through grade 4 (0%) (46) . Two patients out of eleven in the invasive group showed recurrence after the operation, while none of the grade 1 patients recurred. Therefore, AA genotype in cyclin D1 gene may be a marker for invasiveness of prolactinomas, and may also contribute to tumour recurrence. Overexpression of high-mobility group A non-histone chromosomal proteins (HMGA) play a significant role in the determination of chromatin structure. These proteins have been found overexpressed in several cancer types (47) . It has previously been demonstrated that transgenic mice overexpressing HMGA2 develop growth hormone (GH) and prolactin-secreting tumours (48) . With respect to human prolactinomas, aggressive tumours with unresponsiveness to dopamine agonists are associated with higher expression level of this protein (49) .
Role of adhesion molecules
The neural cell adhesion molecules (NCAMs), member of the immunoglobulin superfamily, contribute to cell-to-cell or cell substrate adhesion through homophilic and heterophilic mechanisms (50, 51) . They can be post-translationally modified by polysialylation giving rise to PNCAMs that are implicated in cell growth and migration (52) . PNCAM expression has been noted in aggressive tumours, such as small-cell lung carcinomas, and also some neuroendocrine tumours (53) (54) (55) . The expression of PNCAM has been investigated both in animal models and in human pituitary adenomas. Daniel et al. (56) have investigated the PNCAM expression in four lineages of rat pituitary transplantable tumours (SMtTW) primarily secreting prolactin. They observed the highest PNCAM expression in the lineage SMtTW4 that was characterised by invasion and metastasis. The expression level was correlated with growth rate in different tumour lineages. Embarking from this observation, Trouillas et al. (57) have recently investigated the expression of PNCAMs in a variety of human pituitary tumours in relation to extrasellar invasion using immunohistochemistry, western blot analyses and ELISA. They have observed a positive correlation between tumour invasiveness and PNCAM expression, particularly in the GH-secreting adenomas. This was not the case in the prolactinoma subgroup (nZ14), although some of them expressed PNCAM (57) . The discrepancy between animal and human prolactinomas may be related to differences in tumour invasion mechanisms between species, and the small number of prolactinomas studied in humans.
Tumour cell invasion is a multistep process that requires complex changes in adhesive interactions among cells. The detachment of tumour cells from the primary lesion is thought to be an important initiative step leading to invasion. E-cadherin is an important molecule implicated in tumoural invasion processes (58) . The functions of E-cadherin are mediated through its cytoplasmic linkage to the actin cytoskeleton via certain cytoplasmic plaque proteins known as the catenins (a, b and g) (59, 60) . P120, by binding to E-cadherin as a regulatory factor, enables it to function to promote intercellular adhesion (61) . It is believed that the cadherin/catenin/p120 complex acts as an 'invasion suppressor system'. There are several observations in various cancers indicating its abnormal or reduced expression (62). Qian et al. (63) have shown that expression of E-cadherin and b-catenin seems to be significantly lower in invasive prolactinomas compared with non-invasive ones, and the complex is significantly less expressed in macroadenomas than microadenomas. The tumours derived from men showed a significantly lower level of expression than tumours from women. The decrease in cadherin/catenin expression predicted increased MIB-1 labelling indicative of high proliferative activity. The results of this study indicate that low cadherin/catenin expression may be a useful marker in predicting tumour aggressiveness in prolactinomas (63) . In contrast, Kawamoto et al. (64) have found no significant difference in E-cadherin expression between invasive and non-invasive, non-functioning and GH-secreting pituitary adenomas. It seems therefore that loss of E-cadherin expression may be a marker of invasiveness for prolactinomas but not GH-producing or non-functioning adenomas. The molecular mechanisms responsible for loss of cadherin/catenin expression in invasive prolactinomas are not presently known.
Role of extracellular matrix components (ECM) and degradation of ECM
Components of the extracellular matrix are implicated in pituitary tumourigenesis (65) . Laminin, for example, inhibits the production of prolactin and cell proliferation. Differential expression of laminin has been observed in D2 receptor knockout mice that spontaneously develop aggressive prolactinomas (66) . From the initial formation of hyperplasia, a dramatic reduction occurs in laminin expression with the advancement of tumour progression. The expression of laminin is confined to basal membranes surrounding blood vessels despite the fact that it is abundantly expressed in the normal adenohypophysis parenchyma (66) . The significance of laminin remains to be investigated in human prolactinoma behaviour.
The ECM can be degraded and reorganised by specific enzymes from the family of matrix metalloproteinases (MMPs). The activities of various MMPs are balanced by tissue inhibitors of metalloproteinases (TIMPs) (67) . MMP-2 and MMP-9 are both type IV collagenases that are able to promote tumour invasion by breaking down the basement membrane (68) . The secretion of MMP is also an important early step contributing to endothelial cell migration through degraded ECM enabling angiogenesis to occur (69) . Serine proteases and their modulators (plasminogen activators and inhibitors) are also involved in ECM remodelling by initiating a cascade of events, involving MMP-9 proteolytic activity (70) .
In the context of the biological behaviour of pituitary adenomas, studies investigating the contribution of MMP-9 have yielded conflicting results. Our group has previously demonstrated that MMP-9 expression by macrophages in invasive macroprolactinomas was significantly higher than in non-invasive macroprolactinomas, while expression levels of MMP-9 in pituitary carcinomas was similar to that of invasive adenomas (71) . We have also found a positive correlation between MMP-9 expression and angiogenesis. However, more recently, Knappe et al. (70) found contradictory results with respect to MMP-9 expression and invasiveness in pituitary adenomas. Contrary to our observations, they could not demonstrate a relationship between aggressive behaviour and MMP-9 expression (70). However, they identified that TIMP-2 was overexpressed in noninvasive as compared with invasive adenomas. These observations suggest that inhibitors of MMPs may play an important role in the suppression of aggressive behaviour in pituitary tumours. The discrepancies in MMP-9 data among the cited studies above may have resulted from different techniques used, diversity of tumour subtypes, selected criteria for aggressiveness, and different number of cases studied.
Local growth factor expression In the pituitary, various growth factors are expressed and released into the extracellular matrix (65) . Fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) are implicated in angiogenesis. Another local factor that may be operative in aggressive prolactinoma behaviour is epidermal growth factor (EGF). Anterior pituitary cells normally express EGF, and it has binding sites mainly confined to lactotroph and somatotroph cells (72, 73) . In pituitary tumours, EGF-binding sites are present in 76.5% of prolactinomas and 62.5% of gonadotrophinomas (74) . EGF binding is more frequent in the invasive than non-invasive pituitary adenoma group which includes prolactinomas (exact number not specified), especially in adenomas invading the cavernous sinus. In addition, adenomas including prolactinomas with supra/extrasellar extension show higher EGF-binding sites compared with those without (74) . It seems that EGF is a key factor contributing to pituitary tumour aggressiveness possibly by its ability to modulate cell proliferation. However, since the correlation of EGFbinding sites with prolactinoma invasiveness has not been specifically addressed in this study (74) , more data in prolactinomas are clearly needed to state that EGF receptor expression levels reflect the invasiveness in this particular type of pituitary adenomas.
Role of tumour angiogenesis
Angiogenesis is the process of new vessel development from existing ones and this has been shown to be involved in tumour growth and spreading. In many cancers, increased vascularisation of the tumour has been correlated with poor prognosis and metastatic spread (75) .
Investigations related to angiogenesis in normal pituitary tissues and pituitary adenomas have opened new avenues to understand the biology of aggressiveness. Contrary to expectations, normal pituitary gland is more vascular than tumours as exemplified by low microvessel counts in immunohistochemistry for CD31 and ulex europaeus agglutinin I (UEAI) (76, for review, see 77). It seems possible that pituitary tumours may induce the development of new blood vessels directly from the systemic circulation (77) . Although pituitary tumours are less vascular than normal pituitary tissue, there is a distinction between specific tumour types in respect of vascular density according to tumour size. We have demonstrated that micro-and macroadenomas that secrete GH or ACTH have comparable vascular densities, whereas macroprolactinomas are significantly more vascular than microprolactinomas (76) . The relationship of angiogenesis with pituitary tumour behaviour has also been studied by our group (78) . We have noticed that preoperative serum hormone levels were directly proportional to microvessel density in prolactinomas, but not in GH-secreting tumours. A significantly increased microvessel density was observed in invasive prolactinomas compared with non-invasive ones (78) . These data support the view that microvessel density as assessed by CD31 and UEAI staining is a marker of aggressive behaviour in prolactinomas affecting the clinical outcome (78) . In another study, we have identified a positive relationship between antiapoptotic protein Bcl-2 expression and microvessel density in a group of pituitary adenomas, including prolactinomas (79) . Thus, prevention of programmed cell death and switch to an angiogenic phenotype seem to be associated with tumour progression and invasion.
Genetic alterations leading to aggressiveness
A considerable number of genetic alterations have been implicated in the pathogenesis of prolactinomas. Those that may be associated with aggressive behaviour, are summarised in Table 2 , and discussed below.
The Ras proto-oncogene Pituitary tumours arise from either gain of function mutations, or the overexpression of proto-oncogenes that function in proliferative pathways (80) . The Ras gene codes for a GTP-binding protein that is important in cellular proliferation and differentiation and involved particularly in early stages of tumourigenesis (81) . A case has been reported with a point mutation (Gly12Val) in the Ras gene presenting with recurrent invasive prolactinoma with dopamine agonist resistance (82) . Despite the fact that Ras mutations have been implicated in various human malignancies, they are uncommon in pituitary adenomas (83) and probably not relevant as genetic markers of tumour progression or malignancy.
Common and pituitary-specific tumour suppressor genes The role of tumour suppressor genes in the pathogenesis of pituitary tumours in animal models is well known. In rodent models, knockout of the retinoblastoma gene (RB) or p27Kip1 gene (a gene involved in cell cycle arrest at G1 stage) has been identified as causing pituitary adenomas (84, 85) . In humans, loss of heterozygosity (LOH) on chromosome 13q, the location of the RB gene, has been identified in a small number of pituitary carcinomas (86) . Bates et al. (87) assessed the impact of allelic deletion of various genes by LOH studies. LOH was found at loci 11q13 (the site for the tumour suppressor gene of multiple endocrine neoplasia type 1, MEN-1), 13q12-14, 10q and 1p. About half of the invasive tumours, which included prolactinomas, had at least one allelic deletion at these sites. Of the six tumours with only one deletion, five involved the 11q13 locus suggesting that this is an early event taking place in transition from a noninvasive state into an invasive one (87) . Although the loss of alleles on chromosome 11q13 has been identified in about 10-20% of both sporadic GH-secreting adenomas as well as prolactinomas (88, 89) , subsequent studies have failed to reproduce similar results in terms of mutations in the MEN-1 gene (90, 91) . In a recent study, MEN-1-associated prolactinomas have been found to be more aggressive compared with the sporadic ones (92) , although other studies have previously failed to show significant differences in this regard (93, 94) . Since mutations and deletions thus far identified account for only a small percentage of pituitary tumours, including prolactinomas, it is presently difficult to infer that there is a generalised genetic mechanism for aggressive tumour behaviour.
Genes related to growth factor expression, angiogenesis and tumour progression The relevance of the locus 11q13 with respect to tumourigenesis and tumour progression in the pituitary gland may also be related to the hst gene that was initially identified as a transforming gene in solid malignant tumours (95) . DNA derived from human prolactinomas express transforming activity in heterologous cells and had sequences in close resemblance with those of hst gene (96) . Overexpression of hst gene leads to increased production of FGF-4 (97). Shimon et al. (97) demonstrated the function of the hst gene in rat lactotroph tumour formation and prolactin secretion. They were able to show that lactotrophs in 5 of 14 prolactinomas stained strongly with anti-FGF-4 monoclonal antibodies. Immunoreactive hst product in adenoma cells was observed in three of five invasive prolactinomas, whereas only two of nine non-invasive ones were positive. Interestingly, most of the non-functioning adenomas and other types of functioning adenomas did not present any staining for hst gene product. Furthermore, immunostaining for proliferative marker Ki-67 showed a greater proliferative status in hst-positive adenomas compared with those that are immunonegative for hst (97) . These findings imply a role of hst gene, and its product FGF-4, in cellular proliferation, growth and aggressive behaviour in prolactinomas. 
Edpm5
Variability between rat strains Change in angiogenic switch, alterations in tumour angiogenesis upon oestrogen stimulation
LOH, loss of heterozygosity; bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; PTTG, pituitary tumour-transforming gene.
Oestrogen promotes tumourigenesis in the pituitary gland via induction of a novel pituitary tumourtransforming gene (PTTG) that is located on chromosome 5q33 (98) . PTTG has been shown to be tumourigenic in vivo, by regulating basic fibroblast growth factor (bFGF) secretion and inhibiting chromatid separation (99, 100) . bFGF modulates angiogenesis, tumour formation and progression in several tissues, including the pituitary (101) . Oestrogen induces overexpression of rat PTTG leading to increased bFGF and VEGF production (VEGF) in the pituitary gland (101) . Moreover, bFGF itself has an ability to modulate VEGF expression (101) . This finding implies that oestrogen is important in pituitary adenoma formation and progression via a paracrine mechanism involving angiogenesis. In accordance with these effects of oestrogen, lactotroph tumours tend to enlarge considerably during pregnancy (102) . As noted earlier, prolactinomas in men tend to exhibit a more aggressive course. This seems to be counterintuitative concerning the oestrogen-PTTG pathway, since men have lower oestrogen levels than women. However, this discrepancy may be explained by the observation that although men have lower oestrogen levels, their tumours express more oestrogen receptors than those in women (103) . It should be noted, however, that PTTG overexpression is not specific for prolactinomas, and seen in all classes of hormone-secreting pituitary adenomas (104, 105) . Recently, a novel gene locus named Edpm5 has been shown to prevent the angiogenic switch in prolactinomas after chronic oestrogen treatment in rats (106) . The contribution of Edpm5 gene to angiogenesis and aggressive behaviour in human prolactinomas, however, is yet to be defined.
Genes implicated in resistance to dopamine agonists It is well known that dopaminergic receptor-2 (D2R) gene-deficient mice develop lactotroph cell hyperplasia and tumours capable of massive invasion (107) . No mutation in the D2R gene has been reported in 79 invasive and dopamine agonist-resistant prolactinomas (108) . However, the impact of dopamine receptor gene polymorphisms on prolactinoma behaviour warrants further investigations.
Summary and conclusions
Aggressive prolactinomas represent a group presenting with invasion into surrounding and remote structures and causing challenges in treatment. Invasive tumours are usually associated with lower cure and higher recurrence rates as compared with non-invasive ones. Prolactin levels at diagnosis are higher in these tumours in correlation with their sizes, and naïve or acquired resistance to dopamine agonists are more frequently encountered. Invasive prolactinomas may be associated with increased Ki-67/MIB-1 labelling indices indicating increased cell proliferation, although this is not a universal finding. Increased expression of polysialylated neural cell adhesion molecule and reduced expression of E-cadherin/catenin complex may imply a contribution of changes in cell-to-cell adhesion and cellular migration. The reduced E-cadherin/catenin expression seems to be relatively specific for invasive prolactinomas, but not other functioning and non-functioning pituitary tumours. ECM and MMPs with their inhibitors play important roles in the context of angiogenesis, a key switch factor leading to invasion. The induction of local FGF and VEGF activity via the oestrogen-induced overexpression of novel genes (PTTG, hst and Edpm5) enhance prolactin cell growth, proliferation and tumoural angiogenesis in prolactinomas. hst gene overexpression is relatively specific for invasive prolactinomas. Loss of tumour suppressor genes at various loci, including 11q13 has been found in invasive pituitary adenomas, including prolactinomas. Since only a few specific markers have been identified thus far, more investigations into the mechanisms of aggressive behaviour in prolactinomas are needed to eventually predict cases with poor clinical outcome. New treatment modalities specifically targeting these mechanisms may promise a cure for these challenging tumours.
